<DOC>
	<DOCNO>NCT01393626</DOCNO>
	<brief_summary>This study investigate safety efficacy CP-690,550 adult patient moderate severe Crohn 's disease . The study hypothesis least one dose test drug effective placebo ( inactive drug ) .</brief_summary>
	<brief_title>A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Male female subject age 18 75 year screen ( upper age limit 64 year India 65 year Netherlands ) . Subjects clinical diagnosis Crohn 's disease least 6 month prior screen . Subjects active moderate severe ileal , ileocolic , colonic CD define baseline score Crohn 's Disease Activity Index ( CDAI ) 220 450 baseline . Diagnosis indeterminate colitis , ulcerative colitis ( UC ) , clinical finding suggestive UC . Subjects diagnose Crohn 's disease without previous exposure treatment ( i.e. , treatmentnaïve ) . Subjects receive follow treatment Crohn 's disease : Azathioprine , 6mercaptopurine methotrexate within 2 week prior baseline . AntiTNFα therapy within 8 week prior baseline . Interferon therapy within 8 week prior baseline . Cyclosporine , mycophenolate , tacrolimus within 4 week prior baseline . Intravenous corticosteroid within 2 week prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>